Scandinavian ChemoTech has announced the early publication of an independent clinical abstract ahead of the ECVS congress (July 9–11). The study reports an outstanding 97% complete remission rate for equine sarcoids treated under standing sedation. While we already anticipated encouraging results and leave our financial model unchanged, this data de-risks the commercial roll-out of the vetIQure™ platform.
LÄS MER
